A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01

Overview of attention for article published in BMC Cancer, December 2019

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 1 X post from an account with 0 followers.

A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor an… https://t.co/CFuvXrjhtm

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.